Related Experiment Video
Updated: May 26, 2026

07:17
Single Port Donor Nephrectomy
Published on: March 12, 2011
Single institution experience with robot-assisted laparoendoscopic single-site renal procedures
Rakesh Khanna1, Robert J Stein, Michael A White
1Department of Urology, Glickman Urological and Kidney Institute, Cleveland, OH 44195, USA. khannara@upstate.edu
Journal of Endourology
|December 24, 2011
Summary
Robot-assisted laparoendoscopic single-site (LESS) kidney surgery offers a versatile approach for various procedures. This technique shows promising oncologic outcomes and symptom resolution in patients undergoing renal surgery.
Area of Science:
- Minimally Invasive Surgery
- Urologic Oncology
- Robotic Surgery
Background:
- Laparoendoscopic single-site (LESS) surgery aims to reduce morbidity associated with multiple port sites.
- Challenges in LESS, such as instrument clashing and loss of triangulation, have limited its adoption.
- Robotic platforms are being adapted to overcome LESS limitations in single-site surgery.
Purpose of the Study:
- To review institutional experience with robot-assisted LESS renal surgery.
- To summarize current literature on robot-assisted LESS kidney procedures.
- To assess the feasibility and outcomes of robotic LESS in urology.
Main Methods:
- Review of 28 robot-assisted LESS kidney procedures from a prospectively maintained database.
- Procedures included nephrectomies, nephroureterectomies, pyeloplasties, and renal cyst decortication.
- Analysis of perioperative and postoperative data, including follow-up and oncologic outcomes.
Main Results:
- Four conversions occurred in 28 cases; remaining procedures used no extra trocars.
- Positive oncologic outcomes observed: negative margins and disease-free status for radical nephrectomy, partial nephrectomy, and nephroureterectomy.
- Significant symptom resolution or improvement reported for pyeloplasty patients.
Conclusions:
- Robot-assisted LESS kidney surgery is feasible for a wide range of urologic procedures.
- This approach demonstrates potential for effective oncologic control and symptom management.
- Further long-term follow-up is necessary to confirm oncologic efficacy and durability.

